Literature DB >> 2313851

Blood pressure changes following extracorporeal shock wave lithotripsy and other forms of treatment for nephrolithiasis.

J E Lingeman1, J R Woods, P D Toth.   

Abstract

Hypertension has been reported as a possible sequela of extracorporeal shock wave lithotripsy (ESWL). To evaluate this issue as well as the risk of hypertension following other current non-ESWL treatment options for urolithiasis (percutaneous nephrostolithotomy [PCNL], combined PCNL and ESWL, ureteroscopy, and spontaneous stone passage), detailed blood pressure measurements were made in 961 patients at least 1 year after treatment. All follow-up blood pressures were measured with random-zero blood pressure devices. This study includes 731 patients who received ESWL only (with an unmodified lithotriptor), 171 patients treated with ureteroscopy or spontaneous stone passage (control subjects), 25 patients who received PCNL only, and 34 patients treated with both ESWL and PCNL. In patients who received ESWL only, the annualized incidence of hypertension (2.4%) did not differ significantly from that in control patients (4.0%). Among patients who received ESWL, no correlation was found between the incidence of hypertension and unilateral vs bilateral treatments, the number of shock waves administered, the kilovoltage applied, or the power (number of shock waves times kilovoltage). However, there was a significant rise in diastolic blood pressure after treatment with ESWL (0.78 mm Hg), but not in the control group (-0.88 mm Hg). The long-term significance of this change in diastolic blood pressure following ESWL is unknown and requires further study.

Entities:  

Mesh:

Year:  1990        PMID: 2313851

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  20 in total

1.  Urine cytology to evaluate urinary urothelial damage of shock-wave lithotripsy.

Authors:  Mahmoud Mustafa; Kuddusi Pancaroglu
Journal:  Urol Res       Date:  2010-11-10

2.  Shock wave lithotripsy is not predictive of hypertension among community stone formers at long-term followup.

Authors:  Amy E Krambeck; Andrew D Rule; Xujian Li; Eric J Bergstralh; Matthew T Gettman; John C Lieske
Journal:  J Urol       Date:  2010-11-13       Impact factor: 7.450

3.  Blood pressure changes after extracorporeal shock wave nephrolithotripsy: prediction by intrarenal resistive index.

Authors:  R Knapp; F Frauscher; G Helweg; W Judmaier; H Strasser; G Bartsch; D zur Nedden
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

4.  Evaluation of possible predictive variables for the outcome of shock wave lithotripsy of renal stones.

Authors:  Yong Il Park; Ji Hyeong Yu; Luck Hee Sung; Chung Hee Noh; Jae Yong Chung
Journal:  Korean J Urol       Date:  2010-10-21

5.  A decrease in blood pressure following pyelolithotomy but not extracorporeal lithotripsy.

Authors:  Davor Eterović; Marijan Situm; Ljubica Juretić-Kuscić; Zeljko Dujić
Journal:  Urol Res       Date:  2004-12-24

Review 6.  A systematic review and meta-analysis of new onset hypertension after extracorporeal shock wave lithotripsy.

Authors:  Cui Yu; Liu Longfei; Wang Long; Zeng Feng; Niu Jiping; Li Mao; Qi Lin; Chen Hequn
Journal:  Int Urol Nephrol       Date:  2013-10-27       Impact factor: 2.370

7.  Complications and outcomes following extracorporeal shock wave lithotripsy: a prospective study of 3,241 patients.

Authors:  Sepehr Salem; Abdolrasoul Mehrsai; Hamed Zartab; Nematollah Shahdadi; Gholamreza Pourmand
Journal:  Urol Res       Date:  2009-12-17

Review 8.  Extracorporeal Shock Wave Therapy: Current Perspectives and Future Directions.

Authors:  Andrew C Lawler; Eric M Ghiraldi; Carmen Tong; Justin I Friedlander
Journal:  Curr Urol Rep       Date:  2017-04       Impact factor: 3.092

Review 9.  Reactive oxygen molecules, oxidant injury and renal disease.

Authors:  S P Andreoli
Journal:  Pediatr Nephrol       Date:  1991-11       Impact factor: 3.714

Review 10.  Treatment of urinary tract stones.

Authors:  J E Wickham
Journal:  BMJ       Date:  1993-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.